Consensus Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
11.88 ^USD	-0.17%		-2.54%	-34.40%

Mar. 12	Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	CI
Mar. 05	RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	MT

Evolution of the average Target Price on Pliant Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

47aee5cda.SA_mwkOK6zgudhWg0ut8A6ciRk4ponKQJtVbhbG2z2k.El6upS3kqQ9iAH3NvN8PbPBTECli0TCjSeY_1Mn0glElf6eJJ9KZCGUGYg~7c8e64b9a2519982dd7e5c4b2d32aead

Analyst Recommendations on Pliant Therapeutics, Inc.

RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	Mar. 05	MT
RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk	Feb. 28	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $47 From $49, Maintains Outperform Rating	Feb. 06	MT
HC Wainwright Adjusts Pliant Therapeutics Price Target to $48 From $52, Maintains Buy Rating	Feb. 05	MT
RBC Trims Price Target on Pliant Therapeutics to $53 From $54, Keeps Outperform, Speculative Risk	Nov. 10	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $52 From $50, Maintains Buy Rating	23-09-27	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $52 From $51, Maintains Outperform Rating	23-08-10	MT
RBC Cuts Price Target on Pliant Therapeutics to $54 From $57, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-10	MT
Canaccord Genuity Initiates Pliant Therapeutics at Buy With $48 Price Target	23-05-18	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $51 From $44, Maintains Outperform Rating	23-05-10	MT
RBC Trims Price Target on Pliant Therapeutics to $57 From $58, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-10	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $55 From $54, Maintains Buy Rating	23-05-01	MT
Cantor Fitzgerald Adjusts Pliant Therapeutics Price Target to $63 From $52, Maintains Overweight Rating	23-05-01	MT
Baird Initiates Pliant Therapeutics at Outperform With $44 Price Target	23-04-13	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $54 From $53, Keeps Buy Rating	23-03-20	MT
Citigroup Adjusts Price Target on Pliant Therapeutics to $50 From $55, Maintains Buy Rating	23-03-13	MT
JPMorgan Adjusts Pliant Therapeutics Price Target to $47 From $51, Maintains Overweight Rating	23-03-10	MT
Oppenheimer Adjusts Pliant Therapeutics' Price Target to $44 From $43, Maintains Outperform Rating	23-03-10	MT
RBC Trims Price Target on Pliant Therapeutics to $58 From $60, Maintains Outperform Rating, Speculative Risk	23-03-10	MT
SVB Securities Adjusts Pliant Therapeutics' Price Target to $45 From $33, Keeps Outperform Rating	23-01-24	MT
Citigroup Adjusts Pliant Therapeutics Price Target to $55 From $36, Maintains Buy Rating	23-01-24	MT
Needham Adjusts Pliant Therapeutics' Price Target to $45 From $40, Keeps Buy Rating	23-01-23	MT
Cantor Fitzgerald Adjusts Pliant Therapeutics' Price target to $52 From $40, Keeps Overweight Rating	23-01-23	MT
RBC Boosts Price Target on Pliant Therapeutics to $60 From $50, Maintains Outperform Rating, Assigns Speculative Risk Qualifier	23-01-23	MT
Stifel Starts Pliant Therapeutics at Buy With $33 Price Target	22-12-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.88 USD

Average target price

43 USD

Spread / Average Target

+261.95%

High Price Target

54 USD

Spread / Highest target

+354.55%

Low Price Target

33 USD

Spread / Lowest Target

+177.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pliant Therapeutics, Inc.

RBC Capital Markets
Oppenheimer
HC Wainwright
Canaccord Genuity
Cantor Fitzgerald
Baird
Citigroup
JPMorgan Chase
SVB Securities LLC
Needham & Co.
Stifel Nicolaus
Piper Sandler
Brigantine Advisors

Ratings for Pliant Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar